MURUGAPPAN M (2025) “ROLE OF FDA 483 OBSERVATIONS IN QUALITY MANAGEMENT SYSTEMS: ENHANCING COMPLIANCE AND RISK MANAGEMENT”, Asian Journal of Pharmaceutical and Clinical Research, 18(4), pp. 44–51. doi: 10.22159/ajpcr.2025v18i4.54004.